Table 5.
Factors affecting Helicobacter pylori eradication efficacy.
| Eradication success (N = 130), n (%) | P value | |
|---|---|---|
| Gender | ||
| Female | 59 (45.4) | .061 |
| Fale | 71 (54.6) | |
| Age, year | 43.02 ± 12.84 | .661 |
| Patient type | ||
| Inpatient | 88 (67.7) | .090 |
| Outpatient | 42 (32.3) | |
| Endoscopic findings | ||
| No gastroscopy | 50 (38.5) | .820 |
| Only non-atrophic gastritis | 34 (26.1) | |
| Only atrophic gastritis | 36 (27.7) | |
| Mainly gastritis and esophagitis | 3 (2.3) | |
| Mainly gastritis and gastric ulcer and/or duodenal ulcer | 7 (5.4) | |
| Compliance | ||
| No | 2 (1.5) | .005 |
| Yes | 128 (98.5) | |
| Number of comorbidities | ||
| 0 | 109 (83.8) | .723 |
| 1 | 19 (14.6) | |
| 2 | 2 (1.6) | |
| BMI | 23.84 ± 2.94 | .613 |
| Smoking | ||
| No | 110 (84.6) | .354 |
| Yes | 20 (15.4) | |
| Alcohol drinking | ||
| No | 94 (72.3) | .070 |
| Yes | 36 (27.7) | |
| AEs | ||
| No | 113 (86.9) | .427 |
| Yes | 17(13.1) | |
| Severity of AEs | ||
| No | 113 (86.9) | .560 |
| Mild | 16 (12.3) | |
| Moderate | 1 (0.8) | |
| Treatment therapies | ||
| VA | 68 (52.3) | .196 |
| VBQT | 62 (47.7) | |
| Multivariate analyses (adjusted OR [95% CI]) | ||
| Gender | ||
| Male | Reference | .511 |
| Female | 1.483 (0.458, 4.797) | |
| Patient type | ||
| Outpatient | Reference | .130 |
| Inpatient | 0.471 (0.178, 1.248) | |
| Compliance | ||
| No | Reference | .005 |
| Yes | 14.640 (2.283, 93.879) | |
| Alcohol drinking | ||
| No | Reference | .438 |
| Yes | 0.650 (0.218, 1.933) | |
| Treatment therapies | ||
| VA | Reference | .194 |
| VBQT | 0.544 (0.217, 1.363) | |
Stepwise logistic regression was used for statistical analysis. P value < 0.05 was considered significant.
AE = adverse event, CI = confidence interval, VA = vonoprazan–amoxicillin dual therapy, VBQT = vonoprazan-based bismuth-containing quadruple therapy.